Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors

E. Brissot, M. Labopin, I. Moiseev, J.J. Cornelissen, E. Meijer, G. Van Gorkom, M. Rovira, F. Ciceri, L. Griskevicius, D. Blaise, E. Forcade, M. Mistrik, S. Mielke, C.E. Bulabois, R. Niittyvuopio, E. Deconinck, A. Ruggeri, J. Sanz, A. Spyridonidis, B. SavaniS. Giebel, A. Nagler, M. Mohty

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number87
Number of pages10
JournalJournal of Hematology & Oncology
Volume13
Issue number1
DOIs
Publication statusPublished - 3 Jul 2020

Keywords

  • acute myeloid leukemia
  • antithymocyte globulin
  • blood
  • free survival
  • hematological malignancies
  • matched unrelated donor
  • mechanisms
  • multicenter
  • open-label
  • post-transplant cyclophosphamide
  • prevention
  • prophylaxis
  • skin allograft tolerance
  • versus-host-disease
  • FREE SURVIVAL
  • VERSUS-HOST-DISEASE
  • PROPHYLAXIS
  • Antithymocyte globulin
  • Matched unrelated donor
  • BLOOD
  • MULTICENTER
  • SKIN ALLOGRAFT TOLERANCE
  • PREVENTION
  • OPEN-LABEL
  • MECHANISMS
  • HEMATOLOGICAL MALIGNANCIES
  • Acute myeloid leukemia
  • Post-transplant cyclophosphamide

Cite this